The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene
- PMID: 16091753
- DOI: 10.1038/sj.onc.1208850
The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene
Abstract
Several tyrosine kinase genes are involved in chromosomal translocations in chronic myeloproliferative disorders, but there are still uncharacterized translocations in some cases. We report two such cases corresponding to atypical chronic myeloid leukaemia with a t(8;9)(p22;p24) translocation. By fluorescence in situ hybridisation (FISH) on the corresponding metaphases with a bacterial artificial chromosome probe encompassing the janus kinase 2 (JAK2) gene at 9p24, we observed a split for both patients, suggesting that this gene was rearranged. The locus at 8p22 contains different candidate genes including the pericentriolar material 1 gene (PCM1), already implicated in reciprocal translocations. The rearrangement of the PCM1 gene was demonstrated by FISH, for both patients. By RT-PCR, we confirmed the fusion of 3' part of JAK2 with the 5' part of PCM1. Sequence analysis of the chimeric PCM1-JAK2 mRNA suggests that the putative protein displays the coiled-coil domains of PCM1 and the tyrosine kinase domain of JAK2. This new translocation identifies JAK2 as a possible therapeutic target for compounds with anti-tyrosine kinase activity.
Oncogene (2005) 24, 7248-7252. doi:10.1038/sj.onc.1208850; published online 8 August 2005.
Comment in
-
JAK the trigger.Oncogene. 2005 Nov 3;24(48):7125-6. doi: 10.1038/sj.onc.1208885. Oncogene. 2005. PMID: 16007127
Similar articles
-
The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2.Cancer Res. 2005 Apr 1;65(7):2662-7. doi: 10.1158/0008-5472.CAN-04-4263. Cancer Res. 2005. PMID: 15805263
-
JAK the trigger.Oncogene. 2005 Nov 3;24(48):7125-6. doi: 10.1038/sj.onc.1208885. Oncogene. 2005. PMID: 16007127
-
A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia.Genes Chromosomes Cancer. 2005 Nov;44(3):329-33. doi: 10.1002/gcc.20235. Genes Chromosomes Cancer. 2005. PMID: 16001431 Review.
-
PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation.Leukemia. 2005 Sep;19(9):1692-6. doi: 10.1038/sj.leu.2403879. Leukemia. 2005. PMID: 16034466 No abstract available.
-
[Cytogenetic and molecular monitoring of chronic myeloid leukemia].Orv Hetil. 2006 May 28;147(21):963-70. Orv Hetil. 2006. PMID: 16812971 Review. Hungarian.
Cited by
-
Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application.Biomark Res. 2013 Jan 16;1(1):5. doi: 10.1186/2050-7771-1-5. Biomark Res. 2013. PMID: 24252238 Free PMC article.
-
Enu mutagenesis identifies a novel platelet phenotype in a loss-of-function Jak2 allele.PLoS One. 2013 Sep 25;8(9):e75472. doi: 10.1371/journal.pone.0075472. eCollection 2013. PLoS One. 2013. PMID: 24086539 Free PMC article.
-
Janus kinases in immune cell signaling.Immunol Rev. 2009 Mar;228(1):273-87. doi: 10.1111/j.1600-065X.2008.00754.x. Immunol Rev. 2009. PMID: 19290934 Free PMC article. Review.
-
The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.Blood. 2015 Feb 19;125(8):1282-91. doi: 10.1182/blood-2014-04-570960. Epub 2014 Dec 16. Blood. 2015. PMID: 25515960 Free PMC article.
-
JAK2 tyrosine kinase phosphorylates and is negatively regulated by centrosomal protein Ninein.Mol Cell Biol. 2015 Jan;35(1):111-31. doi: 10.1128/MCB.01138-14. Epub 2014 Oct 20. Mol Cell Biol. 2015. PMID: 25332239 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous